Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medarex, a biopharmaceutical company, has received a milestone payment of an undisclosed amount from its licensing partner, Centocor R&D, for the completion of a Phase II trial of CNTO 95, a fully human antibody targeting the integrin receptors that are implicated in tumor-induced angiogenesis.
Subscribe to our email newsletter
The CNTO 95 human antibody was generated using Medarex’s UltiMAb technology. Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales.
Howard Pien, president and CEO of Medarex, said: “We are pleased with the progress of this program and the potential of technology licensing programs under our partnership with Centocor to contribute to future revenues.”